Valuation of Your Early Drug Candidate: A "No-Formulas" Tour of Valuation

Biotech companies seek partnerships (collaborations, licensing deals, joint ventures, etc) to advance their drug candidates and raise funds. They frequently ask "How much is this drug candidate worth to a partner?"

Early drug candidates, due to numerous factors such as long development timelines before the value is realized, many questions yet unanswered, ever-changing market conditions and regulatory requirements and the high risk of technical failure can be more difficult to value.

In this new whitepaper, author Linda Pullan, reviews the different techniques, key variables, and characteristics of what makes a drug candidate more valuable to a partner. Find out how valuation gets translated to deal terms and get a clear, conceptual framework for your drug's valuation.



By supplying my contact information, I authorize ShareVault to contact me about relevant content, products, and services. We're committed to your privacy, for more information, check out our Privacy Policy.


Company team

Linda Pullan, PhD

Pullan Consulting

Linda offers biotech and
pharmaceutical companies consulting
in all aspects of partnering. Linda has
a Ph.D. in Biochemistry, a B.S. in
Chemistry, and more than twenty
years of drug industry
experience. Learn More

sharevault software or biopharma